6 January 2014
Scancell Holdings Plc
('Scancell' or the "Company")
Nottingham Technology Grant
Scancell Holdings Plc, (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer, is pleased to announce that it has received a Nottingham Technology Grant Fund ("N'Tech") of £80,000 from Nottingham City Council. Funded by the Government's Regional Growth Fund, the grants from N'Tech are awarded mainly to small and medium-sized companies to support business growth and expansion in the Greater Nottingham area. Scancell will use the funds to secure additional staff to develop its groundbreaking new Moditope® technology platform.
Richard Goodfellow, Joint CEO of Scancell, said: "We are delighted to receive this additional funding from Nottingham City Council. This funding will allow us to expand our skill base and boost our productivity at this important juncture in the Company's history."
For Further Information:
Dr Richard Goodfellow, Joint CEO Professor Lindy Durrant, Joint CEO |
Scancell Holdings Plc Scancell Holdings Plc |
+ 44 (0) 20 7831 3113 |
|
|
|
Camilla Hume/Stephen Keys |
Cenkos Securities plc |
+ 44 (0) 20 7397 8900 |
|
|
|
Mo Noonan/Simon Conway |
FTI Consulting |
+ 44 (0) 20 7831 3113 |
About Scancell
Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms. Scancell's first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and has just completed Phase 1/2 clinical trials which demonstrated that SCIB1 produced a melanoma-specific immune response and promising survival trend. A further higher dose study of SCIB1 will take place during 2014.
Scancell's ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.
Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 that destroy tumours without toxicity. The Directors believe that the Moditope® platform could play a major role in the development of safe and effective cancer immunotherapies in the future.
